In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was ach...
CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...